Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZIRCON-CP: 89Zr-TLX250 for ccRCC Detection in China
NCT06750419Phase 3Recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma (ccRCC), sponsored by Telix Pharmaceuticals Limited. Started Nov 2024; status: recruiting.
02
Drugs
89Zr-DFO-girentuximab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06750419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750419.